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Abstract: Malaysia is a multi-ethnic society whereby the impact of pharmacogenetic differences
between ethnic groups may contribute significantly to variability in clinical therapy. One of
the leading causes of mortality in Malaysia is cardiovascular disease (CVD), which accounts for
up to 26% of all hospital deaths annually. Clopidogrel is used as an adjunct treatment in the
secondary prevention of cardiovascular events. CYP2C19 plays an integral part in the metabolism
of clopidogrel to the active metabolite clopi-H4. However, CYP2C19 genetic polymorphism,
prominent in Malaysians, could influence target clopi-H4 plasma concentrations for clinical efficacy.
This study addresses how inter-ethnicity variability within the Malaysian population impacts the
attainment of clopi-H4 target plasma concentration under different CYP2C19 polymorphisms through
pharmacokinetic (PK) modelling. We illustrated a statistically significant difference (P < 0.001) in
the clopi-H4 Cmax between the extensive metabolisers (EM) and poor metabolisers (PM) phenotypes
with either Malay or Malaysian Chinese population groups. Furthermore, the number of PM
individuals with peak clopi-H4 concentrations below the minimum therapeutic level was partially
recovered using a high-dose strategy (600 mg loading dose followed by a 150 mg maintenance dose),
which resulted in an approximate 50% increase in subjects attaining the minimum clopi-H4 plasma
concentration for a therapeutic effect.
Keywords: PBPK; pharmacokinetics; clopidogrel; CVD; Malaysian
1. Introduction
Malaysia is a multi-ethnic society with a population of over 32 million that is comprised of three
predominant ethic groups, namely Malays (50.1%), Chinese (20.8%) and Indians (6.2%) [1]. In a recent
report by the Malaysian National Centre for Adverse Drug Reaction, 13,789 adverse drug reactions
were reported during the period from 2015 to 2016 [2]. Given the mixed ethnicity of Malaysia, the
impact of pharmacogenetic differences amongst ethnic groups may contribute significantly to the
prevalence of toxicity and ineffective clinical therapy [3–5].
One of the leading causes of mortality in Malaysia is cardiovascular disease (CVD), which accounts
for 22.6% and 26.4% of all hospital deaths annually in Ministry of Health Malaysia hospitals and
Malaysian private hospitals, respectively [6]. Among those deaths, ischaemic heart disease accounts
for the majority of all reported cardiovascular mortality, followed by acute myocardial infarction.
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Furthermore, mortality rates have increased steadily since 1990 despite improvements in health
services [6].
Clopidogrel is a second generation thienopyridine antiplatelet drug and a prodrug that is
metabolised through two pathways: initially by CYP2B6, CYP1A2 and CYP2C19 leading to the inactive
carboxylic acid derivative (2-oxo-clopidogrel), and subsequently by CYP2C19, CYP2C9, CYP2B6
and CYP3A4, leading to its active metabolite (clopi-H4) [7] (Figure 1). The active metabolite confers
clopidogrel its therapeutic response by inhibition of adenosine diphosphate-induced aggregation,
which in turn activates the irreversible binding of the platelet P2Y12 receptor [8]. The contribution of
CYP2C19 towards the formation of clopi-H4 has been further confirmed by several studies [9–11] and
contributes 45% of the first step and 20% of the second step of total hepatic biotransformation [12,13].
Since CYP2C19 plays an integral part in the metabolism of clopidogrel, any disruption or modification
in CYP2C19 expression could potentially affect the pharmacokinetic profiles of clopi-H4, hence leading
to effects on its therapeutic response [14].
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Clinically, approximately one-fourth of individuals who are treated with clopidogrel exhibit a 
sub-therapeutic response [15], with the loss-of-function genotype reducing platelet inhibition by 
clopidogrel [16,17] as a result of reduced clopi-H4 levels [12,18]. 
More than 50 genetic variants have been identified for CYP2C19 [19]. The wild-type CYP2C19*1 
allele is related to functional CYP2C19 metabolism, with CYP2C19*2 and *3 being associated with a 
lost-of-function (LOF) [20]. Gain-of-function (GOF) variants have also been identified and are primarily 
related to the CYP2C19*17 variant, which results in higher catalytic activity of CYP2C19 [21]. Thus, 
individuals presenting with the homozygote and heterozygote allelic variants *2/*2, *3/*3, or *2/*3 are 
considered to be representative of poor metaboliser (PM) phenotypes; those with variants *1/*2 or 
*1/*3 (and possibly *2/*17 or *3/*17) are considered intermediate metaboliser (IM) phenotypes; those 
with *1/*1 are considered wild-type or extensive metaboliser (EM) phenotypes and those with *17/*17 
or *1/*17 are considered ultra-rapid metabolisers (UM) [22]. Significant inter-ethnic differences exist 
in the prevalence of these allelic frequencies, with the CYP2C19*2 [23] and CYP2C19*3 [24] alleles in 
the broader Asian populations being significantly higher compared to other racial groups [3,25]. This 
would suggest that Asian population groups would be more likely to be resistant to clopidogrel 
therapy. In European population groups, EM phenotypes predominate with approximately 30% EM 
and 2% presenting as PM [26–28]. Within the Malaysian population group, Chinese and Malays have 
broadly similar prevalence of the *1/*1 genotype, 31.6% and 34.5%, respectively [26–29]. Furthermore, 
*1/*17 genotypes were broadly similar (3.5% and 3.5% for Chinese and Malays respectively). 
However, some differences were noted in the prevalence of genotypes, for example, *1/*2 was greater 
for Chinese (43.9%) compared to Malay (31%) and *1/*3 was higher for Malay (17.2%) compared to 
Chinese (3.5%) [29]. 
LOF genotypes can often result in reduced active metabolite plasma concentrations. For 
example, in a clinical study by Brandt et al. [18], the maximum clopi-H4 plasma concentration (Cmax) 
for wild-type CYP2C19 subjects (n = 56) was 58.4 ± 9.2 ng/mL, compared to CYP2C19*2 carriers, for 
whom the mean Cmax was reported to be 35.3 ± 4.3 ng/mL, a 40% decrease in Cmax. Furthermore, 
pharmacogenetic studies have utilised dose optimisation to counter this reduced clopi-H4 Cmax, 
whereby a loading dose of 600 mg followed by a maintenance dose of 150 mg could partially restore 
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pharmacogenetic studies have utilised dose optimisation to counter this reduced clopi-H4 Cmax,
whereby a loading dose of 600 mg followed by a maintenance dose of 150 mg could partially restore
clopi-H4 to levels observed with a lower loading dose of 300 mg and the standard 75 mg maintenance
dose [9].
The advent of personalised medicine has allowed the clinicians to better respond to the impact
of genetic variability on clopidogrel therapy. However, such genotyping techniques have met with
some contrasting views in relation to their clinic usefulness [30,31]. The impact of anthropometric
difference within a diverse patient population group can further confound the understanding of the
impact of CYP2C19 genetic variability within mixed populations, and these factored together may
significantly alter the pharmacokinetics of drugs. Examples of these factors may include differences
within patient demographics (body weight, age, glomerular filtration rate (GFR)), blood biochemistry
(plasma proteins, haematocrit) and drug metabolism enzyme abundances (CYP abundance and
polymorphism).
Precision medicine allows an individual’s unique physiological characteristics to be incorporated
into treatment options, whereby treatments are tailored to individual patients based on their individual
genetic, biomarker, phenotypic, and psychosocial characteristics [32,33]. To assist in the process of
integrating such a diverse range of anthropometric and genetic factors into clinical decision-making,
the application of pharmacokinetic modelling and simulation has emerged as techniques to better
individualise drug therapy. In particular, the field of population-based physiologically based
pharmacokinetic (PBPK) modelling has rapidly gained traction by drug regulatory authorities
and the wider pharmaceutical industry as a viable means to ‘simulate’ clinical trials and the
pharmacokinetics of drug compounds within virtual population groups representative of individual
population groups [34–39]. Furthermore, the application of PBPK modelling can allow for the
use of population-specific anthropometric variability within virtual subjects, and this was recently
demonstrated by our group when considering the optimisation of anti-malarial therapy in sub-Saharan
African population groups using PBPK-based virtual clinical trials, where the population groups
incorporated anthropometric and biochemical alterations from standard ‘healthy volunteer’ clinical
trials subjects [40,41].
To our knowledge, we present here the first application of PBPK modelling to develop a Malaysian
population group for the specific purpose of understating the impact of genotype drug therapy within
this mixed-ethnicity population. The study directly addresses this inter-ethnicity variability and
provides a research tool that brings together the complexity (at a cellular level) of systems-biology with
the ease-of-use applicability of pharmacokinetic modelling to provide a robust predictive platform
that can easily be adapted and developed as required within the Malaysian population. The objectives
of the present study were two-fold: (i) to predict clopidogrel pharmacokinetics in the Malay and
Malaysian Chinese adult population groups and (ii) to address the impact of the *1/*1, *2/*2, *1/*2
and *1/*17 CYP2C19 genotype on clopidogrel pharmacokinetic.
2. Results
2.1. Step 1: Malaysian Population Group Development
2.1.1. The National Cardiovascular Disease Database
The three largest population groups were selected for analysis and identified as Malay,
Chinese and Indian, with Malay comprising the largest ethnic group contained within the National
Cardiovascular Disease (NCVD) database (Table 1). The mean age, weight and BMI were significantly
different between Malay and Malaysian Chinese (p < 0.0001) and Malaysian Chinese and Malaysian
Indian (p < 0.0001), whereas mean height was relatively consistent across all population groups (1.63 m)
and is not statistically significantly different (Table 1).
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Table 1. Summary demographic data from the NCVD database.
Ethnicity Age (years) Height (m) Weight (kg) BMI (kg/m2)
Malay
Mean 57.75 1.63 69.79 26.19
Median 57.6 1.63 69.5 25.78
N 23114 10250 12193 10170
SD 11.62 0.08 14.24 4.35
Malaysian Chinese
Mean 62.89 1.63 67.17 25.11
Median 63.1 1.63 66 24.79
N 9929 4111 5259 4086
SD 12.04 0.08 13.18 3.84
Malaysian Indian
Mean 57.7 1.63 69.61 25.95
Median 57.3 1.64 69 25.52
N 9167 4257 4809 4229
SD 11.91 0.09 13.91 4.25
N: total number of recorded metrics; SD: standard deviation.
2.1.2. Development of Age–Weight Relationships for Malaysian Populations
Malaysian population groups were subsequently developed for the Malay and Malaysian Chinese
groups. Polynomial mathematical relationship for gender-specific age–weight relationships for the
Malay population group are described in Equations (1) and (2) for 20–65 year olds:
Malay male body weight = −786.757075 + (−105.598305 × age) + 9.79604022 × age1.5
+ (−0.33871491 × age2) + 498.1612119 × age0.5, (1)
Malay female body weight = −3348.57622 + 2424.271248 × age0.5 + (−676.182360 × age)
+ 92.98417478 × age1.5 +( −6.31405170 × age2) + 0.169288237 × age2.5. (2)
Visual predictive checks confirmed that model predicted age–weight relationships retained the
same distribution across age ranges when compared to the NCVD for Malay males (Figure 2A) and
females (Figure 2B).
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Figure 2. Visual predictive checks for the comparison between predicted and observed (NCVD)
age–weight relationship for Mal ale (n = 18,601) (A) and f male (n = 4513) (B) populations. Red
outlined triangles represent the Simcyp predicted population age–weight relationships. Black outlined
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The polynomial mathematical relationship for gender-specific age–weight relationships for the
Malaysian Chinese population group is described in Equations (3) and (4) for 20–65 year olds:
Malaysian Chinese male body weight = (75.50929026 + (−3.86906581 × age)
+ 0.034908233 × age2 + 0.001047109 × age3)/(1 + (−0.04452164 × age)
+ 0.0000141817 × age2 + 0.0000206378 × age3),
(3)
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Malaysian Chinese female body weight = 67.51927661 + (−0.00194867 × age2) +
0.0000000434656 × age4. (4)
Visual predictive checks were performed to assess the graphical qualification between the
polynomial mathematical relationship for age and weight relationships of the software and the
observed Malaysian Chinese male and female populations (Figure 3), and confirmed that model
predicted age–weight relationships retained the same distribution across age ranges when compared
to the NCVD (Figure 3).
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2.2. Step 2: Adult Simulations: Validation with Repaglinide, Tramadol and Rosuvastatin
2.2.1. Repaglinide
The repaglinide compound file within the Simcyp library was used in conjunction with the Simcyp
‘Healthy Volunteer’ population group to predict the plasma concentration–time profile for a single
2 mg oral dose of repaglinide in healthy Caucasian subjects. The resultant predictions were within the
range of observed reported values (Figure 4) with model predicted tmax and Cmax within two-fold of
that reported and AUC within 2.15-fold of the reported (Table 2).
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Subsequently, to further validate model simulations, the ability to predict repaglinide plasma
concentrations following single and multiple dosing was assessed using a healthy volunteer population
group. Predicted plasma concentrations following a single dose (day 1) and multiple doses (day 9) were
within the range reported [43] (Figure 5), with model predicted tmax, Cmax and AUC within two-fold
of those reported [43] (Table 2). However, the terminal elimination phase was poorly predicted.
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doses in healthy adults. An oral dose of 2 mg was administered once daily on day 1, and thereafter daily
for nine days to healthy adult volunteers (n = 12). Solid lines represent mean predictions with dotted
lines representing the 5th and 95th percentile ranges. Open circles represent data for the observed
study at day 1 (single dose) and day 9 (multiple-dosing) [43].
The model was then extended to assess its ap lic tion ithin Malay and Malaysi n Chinese
population groups. For the Malaysian Chinese po ulation, we utilised the cust mised Malaysian
Chinese population group in the model to predict repaglinide plasma concentrations following a
single 2 mg oral dose (Figure 6). The predicted repaglinide plasma concentration was within the range
reported with model predicted tmax, Cmax and AUC within two-fold of those reported [43] (Table 2).
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dotted lines representing the 5th and 95th percentile ranges. Open circles represent data for the
observed study [44].
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For the Malay population group, model predicted Cmax and tmax were within the range reported
(Figure 7) with clearance (CL) predictions within two-fold of that reported and AUC 2.25-fold of that
reported [45] (Table 2).
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Figure 7. Simulated plasma concentration–time profile of repaglinide in healthy Malay adults. A 4 mg
oral dose of repaglinide was administered once daily to adult healthy Malay volunteers (n = 121) using
the custom Malay Simcyp population group. Solid lines represent mean predictions with dotted lines
representing the 5th and 95th percentile ranges. Open circles represent data for the observed study [45].
2.2.2. Tramadol
Tramadol pharmacokinetics have been reported in mixed Malaysian subjects following an IV
bolus dose [46]. Furthermore, T’jollyn et al. [47] have developed and validated a tramadol compound
within Simcyp, and these studies were used as the basis for predicting tramadol pharmacokinetics
in the Malay and Malaysian Chinese populations. Following a 100 mg IV-bolus dose of tramadol,
simulated plasma concentrations for Malays and Malaysian Chinese were within the range reported by
Gan et al. [46] (Figure 8) with model predicted CL and AUC within two-fold of that reported (Table 2).
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Figure 8. Simulated plasma concentration–time profile of tramadol intravenous bolus dosing in Malay
and Malaysian Chinse subjects. An IV-bolus dose of 100 mg tramadol was administered to adult
healthy mixed Malaysian volunteers (n = 100) using the custom Malaysian (Malay and Malaysian
Chinese) Simcyp population group. Solid lines represent mean predictions with dotted lines represent
the 5th and 95th percentile ranges. Open circles represent data for the observed study [46].
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2.2.3. Rosuvastatin
Rosuvastatin pharmacokinetics have been reported in Caucasian and Asian (Chinese and Malay)
subjects following a 40 mg oral dose [48]. Using the rosuvastatin compound within the Simcyp library,
simulated plasma concentration–time profiles for all subjects were within the range reported by Lee et
al. [48] (Figure 9), with model predicted Cmax, tmax and AUC within two-fold of that reported (Table 2).
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Figure 9. Simulated plasma concentration–time profile of rosuvastatin in (A) Caucasian, (B) Chinese
and (C) Malay subjects. A single 40 mg oral dose was administered to adult population groups (n = 36
for each population group, matching the reported study recruitment for each population group) using
the Simcyp Heathy Volunteer (Caucasian), Simcyp Healthy Chinese (Chinese) and custom Malay
population groups. Solid lines represent mean predictions with dotted lines representing the 5th
and 95th percentile ranges. Open circles represent mean data for the observed study with error bars
indicating standard deviation where reported by Lee et al. [48] (and largely missing in results presented
by Lee et al. for Malay subjects).
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Table 2. Summary of predicted and observed pharmacokinetic parameters of repaglinide, tramadol and rosuvastatin.
Compound Validation CL (L/h) Cmax (ng/mL) tmax (h) AUC (ng/mL·h)
Observed Predicted Observed Predicted Observed Predicted Observed Predicted
Repaglinide
Hatorp et al., (2002)
(Healthy volunteers) - 12.17 (10.03–14.77) 26.0 µg/L
32.9 (16.4–47.0)
µg/L 0.83 (0.31–1.35) 0.54 (0.18 -0.91)
152.4 (62.8–242.0)
µg/L·h
70.89 (15.51–73.82)
µg/L·h
Hatorp et al., (1999)
(Single dose)
(Healthy volunteers)
- 13.9 (10.33–18.70) 47.9 (15.9–79.9) 26.2 (19.61–35.0) 0.8 (0.2–1.4) 0.47 (0.31–0.60) 69.0 (61.2–76.8) 54.87 (21.57–106.1)
Hatorp et al., (1999)
(Multiple doses)
(Healthy volunteers)
- 15.32 (12.24–20.57) 58.5 (8.1–108.9) 26.39 (11.53–46.85) 0.6 (0.5–0.7) 0.48 (0.32–0.61) 98.1 (84.54–111.66) 56.8 (22.59–109.1)
Zhai et al., (2013)
(Chinese) 1 -
56.66 (21.10–146.00)
(Malaysian Chinese) 20.0 (14.9–25.1)
18.5 (8.79–28.0)
(Malaysian
Chinese)
1.2 (0.5–1.9)
0.93 (0.82–1.08)
(Malaysian
Chinese)
46.3 (31.2–61.4)
39.51 (16.21–74.56)
(Malaysian
Chinese)
Ruzilawati et al., (2010)
(Malay) 11.82 (7.86–15.78) 10.41 (5.29–15.53)
83.56
(55.63–111.49) 67.5 (34.4–118) 0.62 (0.24–1.00) 0.58 (0.20–0.96)
340.66
(226.14–455.18) 151 (33.61–196)
Tramadol
Gan et al., (2002) 2
(Malaysian)
19.3 (13.1–25.5)
19.24 (13.31–33.11)
(Malay) - - - -
5078.4
(3117.3–7039.5)
4389 (2915–6128)
(Malay)
18.36 (11.73–30.19)
(Malaysian Chinese) - - - -
4716 (3201–6658)
(Malaysian
Chinese)
Rosuvastatin
Lee et al., (2005)
(Malay, Chinese, Healthy
volunteers Caucasians)
-
21.87 (19.49–24.53)
(Malay)
50.0 (42.2–59.3)
(Malay)
49.91 (42.68–58.36)
(Malay)
3.00 (0.50–5.00)
(Malay)
3.01 (2.51–3.61)
(Malay)
413 (354–482)
(Malay)
552.84
(473.51–645.46)
(Malay)
21.28 (19.17–23.63)
(Chinese)
59.1 (49.8–70.1)
(Chinese)
53.83 (42.01–57.35)
(Chinese)
3.00 (0.50–5.00)
(Chinese)
2.90 (2.43–3.45)
(Chinese)
500 (428–583)
(Chinese)
553.18
(475.13–644.05)
(Chinese)
23.99 (22.40–25.70)
(Healthy volunteers) 25.0 (21.1–29.6) 13.49 (10.55–14.28) 5.00 (1.00–8.00) 2.99 (2.15–3.16) 216 (186–252)
116.15
(98.70–136.68)
Data presented as mean (range). 1 Validation study was reported within a Chinese population group. Simulations were performed within a Malaysian Chinese group for comparison;
2 Validation study was reported within a Malaysian population group without demarking ethnicities. Simulations were performed in Malay and Malaysian Chinese for comparison.
CL: Oral clearance; Cmax: maximum plasma concentration; tmax: time to maximum plasma concentration; AUC: area under the plasma concentration–time curve.
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2.3. Step 3: Prediction of the Impact of CYP2C19 Polymorphisms on Clopidogrel Pharmacokinetics in
Malaysians
To assess the impact of CYP2C19 SNPs on target clopi-H4 plasma concentrations
(0.81–13.45 ng/mL) [49] simulations were conducted in Malay and Malaysian Chinese populations to
assess the number of subjects within this therapeutic window. For these simulations, the lowest range
of 0.81 ng/mL was used as a cut-off value to depict patients who were unresponsive to clopidogrel
treatment. A loading dose of 300 mg was administered on day 1 and a maintenance dose of 75 mg
once daily commenced from day 2 to day 5 and was administered to 400 subjects, each possessing
either *1/*1, *2/*2, *1/*2 or *1/*17 genotypes (40 × 10 trials, 100 subjects per genotypes). This was
conducted for both the Malay and the Malaysian Chinese population groups.
Within the Malay population, three subjects of *1/*1 genotype did not reach the target
concentration, followed by 27 subjects with the *2/*2 genotype, 7 subjects with the *1/*2 genotype
and three subjects with the *1/*17 genotype (Figure 10). In the Malaysian Chinese population, the
number of subjects who did not reach the target concentration followed a similar pattern to that of the
Malay population, with three subjects for the *1/*1 genotype, 28 subjects for the *2/*2 genotype, seven
subjects for the *1/*2 genotype and four subjects for the *1/*17 genotype (Figure 10).
There were no statistically significant differences between Malay and Malaysian Chinese when
comparing clopi-H4 Cmax or Cmin concentrations in each phenotype (Figure 10). However, as expected,
in both Malay and Malaysian Chinese populations, the *2/*2 (PM) phenotype resulted in a statistically
significant difference in mean clopi-H4 Cmax when compared to all other phenotypes (p < 0.001).
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Figure 10. (A) impact of clopidogrel standard dose regimens on final dose clopi-H4 plasma Cmax 
(upper panels) and Cmin (lower panels) in Malay (left panels) and Malaysian Chinese (right panels) 
subjects, demarked for all EM, PM, IM or UM populations. Box and whisker plots represent 
maximum, 75th percentile, median, 25th percentile and minimum clopi-H4 Cmax; (B) simulated mean 
plasma concentration–time profile of clopi-H4 in Malay (left panel) and Malaysian Chinese (right 
panel) subjects demarked for all EM, PM, IM or UM populations. All subjects (n = 100 for each 
phenotype) received a loading dose of 300 mg on day 1, followed by daily doses of 75 mg for four 
days. Solid lines represent mean plasma concentration–time predictions. Dashed horizontal lines 
represent the lower therapeutic limit for clopi-H4. 
2.4. Step 4: Sensitivity Analysis for CYP2C19 Hepatic Abundances 
Considering the lack of literature on reported CYP2C19 hepatic abundance data for Malays,  
the sensitivity of model predictions to changes in CYP2C19 hepatic abundance (assuming they varied 
from the default assumption that Chinese and Malay CYP2C19 abundances were similar) was 
assessed through simulating the number of subjects attaining target clopi-H4 concentrations when 
the hepatic mean enzyme abundances were increased or decreased by 30%. In the Malay population, 
a 30% increase in mean abundance values resulted in 2, 27, 6 and 1 subjects failing to reach the target 
concentration for the *1/*1, *2/*2, *1/*2 and *1/*17 genotypes, respectively (Figure 11). Furthermore, a 
30% decrease of mean abundance values resulted in 6, 27, 8 and 6 subjects failing to reach the target 
concentration for the *1/*1, *2/*2, *1/*2 and *1/*17 genotypes, respectively (Figure 11). 
 
Figure 10. (A) impact of clopidogrel standard dose regimens on final dose clopi-H4 plasma Cmax
(upper panels) and Cmin (lower panels) in alay (left panels) and alaysian Chinese (right panels)
subjects, demarked for all EM, PM, I or UM populations. Box and whisker plots represent maximum,
75th percentile, median, 25th percentile and minimum clopi-H4 Cmax; (B) si ulated ean plasma
concentration–time profile of clopi-H4 in Malay (left panel) and Malaysian Chinese (right panel)
subjects demarked for all EM, PM, I or UM populations. All subjects (n = 100 for each phenotype)
received a loading dose of 300 mg on day 1, followed by daily doses of 75 mg for four days. Solid lines
represent mea plasma concentration–time predictions. Dashed horizontal lines represent the lower
therap utic limit for clopi-H4.
2.4. Step 4: Sensitivity nalysis for P2 19 epatic bundances
onsidering the lack of literature on reported CYP2C19 hepatic abundance data for Malays, the
sensitivity of model predictions to changes in CYP2C19 hepatic abundance (assuming they varied
fro the default assumption that Chinese and Malay CYP2 19 abundances were similar) was assessed
through simulating the number of subjects attaining target clopi-H4 concentrations when the hepatic
mean enzy e abundances were increased or decreased by 30%. In the Malay population, a 30%
increase in mean abundance values resulted in 2, 27, 6 and 1 subjects failing to reach the target
concentration for the *1/*1, *2/*2, *1/*2 and *1/*17 genotypes, respectively (Figure 11). Furthermore,
a 30% decrease of mean abundance values resulted in 6, 27, 8 and 6 subjects failing to reach the target
concentration for the *1/*1, *2/*2, *1/*2 and *1/*17 genotypes, respectively (Figure 11).
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Figure 11. Impact of clopidogrel standard dose regimens on final dose clopi-H4 plasma Cmax (upper 
panels) and Cmin (lower panels) in Malay subjects under scenarios where mean hepatic CYP2C19 
abundance is increased (left panels) or decreased (right panels) by 30%. All subjects are demarked for 
either all EM, PM, IM or UM populations. Box and whisker plots represent maximum, 75th percentile, 
median, 25th percentile and minimum clopi-H4 Cmax. All subjects (n = 100 for each phenotype) 
received a loading dose of 300 mg on day 1, followed by daily doses of 75 mg for four days. Dashed 
horizontal lines represent the lower therapeutic limit for clopi-H4. 
For the Malaysian Chinese population, a 30% increase in the mean abundances values resulted 
in 3, 27, 6 and 1 subjects failing to reach the target concentration for the *1/*1, *2/*2, *1/*2 and *1/*17 
genotypes, respectively (Figure 12). Furthermore, a 30% decrease in the mean abundance values 
resulted in 6, 27, 8 and 6 subjects failing to reach the target concentration for the *1/*1, *2/*2, *1/*2 and 
*1/*17 genotypes, respectively (Figure 12). There were also no statistically significant inter-ethnic 
differences between the clopi-H4 peak and trough concentrations for each genotype. 
 
Figure 11. Impact of clopidogrel standard dose regimens on final dose clopi-H4 plasma Cmax (upper
panels) and Cmin (lower panels) in Malay subjects under scenarios where mean hepatic CYP2C19
abundance is increased (left panels) or decreased (right panels) by 30%. All subjects are demarked for
either all EM, PM, IM or UM populations. Box and whisker plots represent maximum, 75th percentile,
median, 25th percentile and minimum clopi-H4 Cmax. All subjects (n = 100 for each phenotype) received
a loading dose of 300 mg on day 1, followed by daily doses of 75 mg for four days. Dashed horizontal
lines represent the lower therapeutic limit for clopi-H4.
For the Malaysian Chinese population, a 30% increase in the mean abundances values resulted in
3, 27, 6 and 1 subjects failing to reach the target concentration for the *1/*1, *2/*2, *1/*2 and *1/*17
genotypes, respectively (Figure 12). Further ore, a 30 decrease in the mean abundance values
resulted in 6, 27, 8 and 6 subjects failing to reach the target concentration for the *1/*1, *2/*2, *1/*2
and *1/*17 genotypes, respectively (Figure 12). There were also no statistically significant inter-ethnic
differences between the clopi-H4 peak and trough concentrations for each genotype.
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Figure 12. Impact of clopidogrel standard dose regimens on final dose clopi-H4 plasma Cmax (upper 
panels) and Cmin (lower panels) in Chinese subjects under scenarios where mean hepatic CYP2C19 
abundance is increased (left panels) or decreased (right panels) by 30%. All subjects are demarked for 
either all EM, PM, IM or UM populations. Box and whisker plots represent maximum, 75th percentile, 
median, 25th percentile and minimum clopi-H4 Cmax. All subjects (n = 100 for each phenotype) 
received a loading dose of 300 mg on day 1, followed by daily doses of 75 mg for four days. Dashed 
horizontal lines represent the lower therapeutic limit for clopi-H4. 
2.5. Step 5: Dose Optimization in CYP2C19 Poor Metabolisers 
Given the high number of subjects identified with clopi-H4 concentrations below the target 
threshold (Figure 10) in the PM phenotype group, the dosing regimen for clopidogrel was increased 
to a ‘high-dose’ scenario with a 600 mg loading dose followed by a four-day regimen of 150 mg daily 
(Figure 13). For a standard dose, 27 Malay and 28 Malaysian Chinese subjects had a clopi-H4 plasma 
concentration below the target minimum therapeutic concentration (Figure 10), which decreased to 12 
(Malay) and 14 (Malaysian Chinese) for the high dose regimen (Figure 13A). No statistically significant 
differences were determined between Malay and Malaysian Chinese clopi-H4 Cmax (Figure 13B). 
 
Figure 12. Impact of clopidogrel standard dose regimens on final dose clopi-H4 plasma Cmax (upper
panels) and Cmin (lower panels) in Chinese subjects under scenarios where mean hepatic CYP2C19
abundance is increased (left panels) or decreased (right panels) by 30%. All subjects are demarked for
either all EM, PM, IM or UM populations. Box and whisker plots represent maximum, 75th percentile,
median, 25th percentile and minimum clopi-H4 Cmax. All subjects (n = 100 for each phenotype) received
a loading dose of 300 mg on day 1, followed by daily doses of 75 mg for four days. Dashed horizontal
lines represent the lower therapeutic limit for clopi-H4.
2.5. Step 5: Dose Optimization in CYP2C19 Poor Metabolisers
Given the high number of subjects identified with clopi-H4 concentrations below the target
threshold (Figure 10) in the PM phenotype group, the dosing regimen for clopidogrel was increased to
a ‘high-dose’ scenario with a 600 mg loading dose followed by a four-day regimen of 150 mg daily
(Figure 13). For a standard dose, 27 Malay and 28 Malaysian Chinese subjects had a clopi-H4 plasma
concentration below the target minimum therapeutic concentration (Figure 10), which decreased to 12
(Malay) and 14 (Malaysian Chinese) for the high dose regimen (Figure 13A). No statistically significant
differences were determined between Malay and Malaysian Chinese clopi-H4 Cmax (Figure 13B).
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Figure 13. (A) impact of clopidogrel high dose regimen on clopi-H4 plasma Cmax in Malay (left panel) 
and Malaysian Chinese (right panel) subjects; (B) simulated mean plasma concentration–time profile 
of clopi-H4 in Malay (left panel) and Malaysian Chinese (right panel) subjects. An oral loading dose of 
600 mg was administered on day 1, followed by daily doses of 150 mg for four days using the custom 
Malaysian (Malay and Malaysian Chinese) Simcyp population group (n = 100), with dosing to 
populations of either all PM or all EM phenotypes. Solid plasma concentration lines represent mean 
predictions. Dashed horizontal lines represent the lower therapeutic limit for clopi-H4. Box and whisker 
plots represent maximum, 75th percentile, median, 25th percentile and minimum clopi-H4 Cmax. 
3. Discussion 
Cardiovascular disease (CVD) is a leading global cause of mortality with recent reports 
highlighting that approximately 85% of CVD cases occur in low- to middle-income countries [50,51]. 
A primary cause of this increase is related to changes in economic development and lifestyle with 
reduced incidences of infectious diseases, all of which has led to a marked improvement in the life 
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Figure 13. (A) impact of clopidogrel high dose regimen on clopi-H4 plasma Cmax in Malay (left panel)
and Malaysian Chinese (right panel) subjects; (B) simulated mean plasma concentration–time profile
of clopi-H4 in Malay (left panel) and Malaysian Chinese (right panel) subjects. An oral loading dose
of 600 mg was administered on day 1, followed by daily doses of 150 mg for four days using the
custom Malaysian (Malay and Malaysian Chinese) Simcyp population group (n = 100), with dosing to
populations of either all P or all E phenotypes. Solid plasma concentration lines represent mean
predictions. Dashed horizontal lines represent the lower therapeutic limit for clopi-H4. Box and whisker
plots represent aximum, 75th percentile, median, 25th percentile and minimum clopi-H4 Cmax.
3. Discussion
Cardiovascular disease (CVD) is a leading global cause of mortality with recent reports
highlighting that approximately 85% of CVD cases occur in low- to middle-income countries [50,51]. A
primary cause of this increase is related to changes in economic development and lifestyle with reduced
incidences of infectious diseases, all of which has led to a marked improvement in the life expectancy
of low- to middle-income countries from 61.7 years in 1980 to 71.8 years in 2015 [50]. Furthermore,
the higher incidences of non-communicable disease, such as diabetes mellitus, hypertension and
dyslipidaemia, have all contributed to an overall increase in the incidence of CVD in low- to
middle-income countries.
Despite these risks, the Ministry of Health (MOH) Malaysia has a proactive stance in relation
to CVD and has maintained a long-standing database of cardiovascular disease in Malaysia, which
is utilised to evaluate risk factors and treatment within Malaysia. The National Cardiovascular
Database (NCVD) Registry [6] ensures the ongoing systematic collection, analysis and interpretation
of cardiovascular disease data essential, which is essential and core to planning, implementation and
evaluation of clinical and public health services within Malaysia. The NCVD was officially launched
in 2006 by Dr. Ghani Mohamed Din (Deputy Director General of Health Malaysia) during the 10th
Annual Scientific Meeting (ASM) of the National Heart Association of Malaysia (NHAM). To date, the
NCVD register consists of 33,043 anonymised and voluntary patient records for patients undergoing
acute coronary syndrome and percutaneous coronary intervention, spanning the years 2006–2015.
Although aspirin remains a primary treatment option for many CVD related disorders due to
its cost-effectiveness [52], a key reason for clinicians moving towards a second-line therapy is often
hypersensitivity of patients towards aspirin. In Malaysia, clopidogrel is recommended as a second-line
therapy for ischemic cardiovascular events and also secondary prevention of ischemic stroke [53,54].
Clopidogrel is an antiplatelet agent, being predominantly metabolised into the active metabolite
clopi-H4, primarily mediated by CYP2C19 [9–11]. However, CYP2C19 is highly polymorphic [55], with
the PM phenotypes (*2/*2) known to be of higher prevalence in Asian populations when compared to
Caucasians [56,57].
Outside of Southeast Asia, the use of predictive pharmacokinetics modelling to aid in both
drug discovery and development along with clinical optimisation of drug therapy has exponentially
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increased over the past decade and has become a routine aspect of all clinical trials phases to both
extrapolate dose to optimal therapy in population groups and to also identify covariates that may
contribute to the variability in clinical response to drugs [58–60]. However, within Malaysia, the use of
pharmacokinetic modelling to conduct such beneficial models’ approaches is lacking.
Recently, we demonstrated the ability of physiologically-based pharmacokinetic modelling
to optimise dosing of antimalarial drugs in special population groups from sub-Saharan African
nations [40,41,61], where the unique physiological and anthropometric differences of African subjects
(when compared to Caucasians) were incorporated into simulations. We have adapted this approach to
now develop, for the first time, an appropriate virtual population group of the Malaysian population
group for use in mechanistic pharmacokinetic modelling, with a focus on predicting the impact of
CYP2C19 SNPs on clopidogrel and the active metabolite, clopi-H4, pharmacokinetic in the Malay and
Malaysian Chinese population groups.
We adopted a robust 5-stage modelling approach that incorporated key data from the Malaysian
NCVD database to develop virtual population groups, following validation of the modelling
approaches using repaglinide, tramadol and rosuvastatin within healthy volunteers (Caucasian),
Chinese and Malay population (Steps 1 and 2), followed by the simulation of clopidogrel and its active
metabolite, clopi-H4 in the Malay and Malaysian Chinese population groups (Step 3). Next, the impact
of CYP2C19 SNPs on the active metabolite, clopi-H4 in the Malay and Malaysian Chinese population
groups were assessed with predictions of potential exposure to the clopidogrel therapy (Step 4). Finally,
simulations were conducted to predict the potential impact of dosage optimisation in the CYP2C19
PM population (Step 5).
3.1. Step 1: Malaysian Population Development
In Step 1, we attempted to develop a representative Malaysian population by extracting relevant
data such as gender, weight, age and ethnicity from the NCVD database [6], with which to develop
the populations. For the Malay, Chinese and Indian population, the mean age, weight and BMI were
significantly different between Malay and Chinese (p < 0.0001) and Chinese and Indian (p < 0.0001),
whereas mean height was relatively consistent across all population group at 1.63 m and not statistically
significantly different (Table 1). Since there was no significant difference between the heights of all
the three populations, the default age–height relationship for the ‘Chinese Volunteer’ population
group within Simcyp was used to represent these populations. Using the customised age–weight
relationships for the two populations, the predicted distribution of body-weight with age for both the
Malay (Figure 2) and Malaysian Chinese (Figure 3) populations was predicted well and in good
agreement with individual subject data extracted from the NCVD data over the range of 20 to
65 years of age. This supports the development of appropriate population groups possessing suitable
anthropometric age–weight relationship within the Malaysian population. In addition, this step
incorporated appropriate blood biochemistry metrics to describe Malay and Malaysian Chinese
population groups, something which is critical for driving unbound drug fraction within plasma
and essential as clopidogrel, and its metabolites are extensively protein bound (see Section 4.1.1
Table 3) [62,63].
Table 3. Malay and Malaysian Chinese blood biochemistry.
Biochemistry Malay Malaysian Chinese
Haematocrit (%) M: 43 b F: 38 c M: 45.3 F: 40.5
AAG (g/L) M: 0.65 a F: 0.64 a M: 0.65 F: 0.64
HSA (g/L) M: 47.3 b F: 46.3 b M: 50.34 F: 49.38
AAG: α1-acidic glycoprotein; HSA: human serum albumin M: male; F: female; a Simcyp default values;
b Hamzah et al. [64]; c Khor et al. [65].
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3.2. Step 2: Adult Simulations: Validation with Repaglinide, Tramadol and Rosuvastatin
Having established a Malaysian virtual population group for use in predictive pharmacokinetic
modelling, we subsequently assessed the ability of the customized population groups to predict
repaglinide and tramadol plasma concentrations and pharmacokinetics in the Malay (Figure 7), Chinese
(Figure 6) and Caucasian Healthy Volunteers (Figures 4 and 5) populations. In these simulations,
model predictions were successfully predicted to within two-to-three-fold, Cmax, tmax, CL and AUC
was reported (Table 2) [44,45], and an appropriate population distribution was recapitulated. It was
noted, however, that in Caucasians the model predicted a poorer terminal elimination phase of the
plasma concentration–time profile when multi-dosing (Figure 5). This may, in part, be a result of the
original study reporting plasma concentration–time profiles without using a log-linear scale, making
precise determination of terminal points difficult. However, it should be noted that the AUC was
predicted to within two-fold of that reported [43].
Subsequently, the customised Malay and Malaysian Chinese population group were further
validated against a study whereby an IV bolus dose of tramadol was dosed to Malaysian subjects [46].
Model prediction AUC and Clearance were within two-fold of that reported (Table 2) with model
predicted plasma concentration–time profiles spanning an appropriate range for the simulated
population group when compared to the observed data (Figure 8). Finally, model validation was further
confirmed through successful prediction of rosuvastatin plasma concentrations and pharmacokinetics
in Caucasian, Chinese and Malays (Figure 9) with predicted Cmax, tmax, and AUC to within two-fold
of that reported [48] (Table 2).
3.3. Step 3: Prediction of the Impact of CYP2C19 Polymorphisms on Clopidogrel Pharmacokinetics
in Malaysians
Having successfully validated the predicting capability of the customised population groups
within pharmacokinetic models for repaglinide and tramadol, the model was expanded to assess its
application to predict clopidogrel and its active metabolite, clopi-H4, pharmacokinetics in Malaysian
subjects. In an attempt to establish the potential impact of CYP2C19 SNPs on clopi-H4 plasma
concentration in Malay and Malaysian Chinese populations, we conducted simulations stratified
across EM, PM, IM, and UM phenotypes. A statistically significant difference in the clopi-H4 Cmax
was predicted between the EM and PM groups within the Malay and Malaysian Chinese population
(Figure 10), with clopi-H4 Cmax decreasing by approximately 50% in the PM population groups
compared to the EM population group in both Malay and Malaysian Chinese (Figure 10).
In a study by Simon et al. [9], clopi-H4 plasma concentrations were quantified for each phenotype
in European subjects. Following a standard dose (300 mg loading dose followed by 4 days of 75 mg once
daily), the last dose mean Cmax was 13 ± 7.33 ng/mL for EM and 3.93 ± 1.93 ng/mL for PM. In both
Malay and Chinese subjects, the median last dose Cmax was significantly lower for EM (2.60 ng/mL
and 2.55 ng/mL) (Figure 10A). However, the overall range of predicted Cmax was similar to those
reported [9]. This difference, however, may be attributed to the anthropometric differences between
Southeast Asian/Far East Asian population groups and European (Caucasian) populations [66] in
addition to differences in the prevalence of each genotype [23–28].
Similar reports for Malaysians subjects are currently lacking. However, in mainland Chinese subjects,
clopi-H4 Cmax for the study duration (i.e., first dose) was reported to be 18.9 ng/mL ± 11.8 ng/mL in EM
(*1/*1) and 11.8 ng/mL ± 5.1 ng/mL in PM (*1/*2 or *2/*2) [67], within three-fold of the simulated
mean Cmax for EM (8.62 ng/mL ± 11.4 ng/mL) and PM (5.59 ng/mL ± 3.92 ng/mL) (Figure 10B)
whilst also being within a similar range of observed concentrations, when taking into account the
standard deviations reported for Cmax [67].
No significant differences were observed in clopi-H4 plasma concentrations between the
Malaysian Chinese and Malay populations when comparing CYP2C19-genotyped groups (Figure 10).
This finding is consistent with reports of a similar frequency of CYP2C19 metaboliser groups between
the Malay and Malaysian Chinese in a cohort of Malaysian patients taking clopidogrel [29,68,69]. Thus,
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although the impact of the CYP2C19 polymorphism on clopidogrel pharmacokinetic may lead to
treatment failure in PM within the Malay and Malaysian Chinese population, due to the attenuation
of clopi-H4 plasma concentration, the magnitude of this impact between these populations is largely
minimal, with insignificant differences observed between them (Figure 10).
3.4. Step 4: Sensitivity Analysis for CYP2C19 Hepatic Abundances
Despite CYP2C19 polymorphisms having been previously characterised for Malaysians, the
hepatic abundance of CYP2C19, and how it varies from Caucasian subjects, is currently lacking.
Within the context of pharmacokinetic modelling, this is an important quantitative metric, allowing
both the prediction of in vivo clearance (from in vitro hepatocyte/microsomal incubations) and,
when combined with appropriate phenotype/genotype data, the ability to model the impact of
polymorphisms on resultant drug pharmacokinetics. However, for the Chinese population group,
hepatic CYP2C19 abundance has been quantified along with phenotype-specific abundances (8, 0, 6
and 10 pmol/mg protein for EM, PM, IM and UM, respectively), and these have been incorporated into
the Simcyp population database and characterised/validated by Simcyp and other researchers [70,71].
However, comparisons to other Asian population groups (e.g., Japanese) show variations in
the hepatic abundance for EM phenotypes (14 pmol/mg for Caucasians; 9 pmol/mg for Chinese;
1 pmol/mg for Japanese) [71]. Given this variation, it was prudent to simulate the impact of variation
in CYP2C19 EM and PM phenotype abundance, and this was accomplished through applying a 30%
increase and 30% decrease of mean abundance values for all CYP2C19-phenotyped groups in the
Malay (Figure 11) and Chinese population (Figure 12).
With a 30% increase in mean abundances, there was a slight increase in patient’s response towards
clopidogrel treatment based on the clopi-H4 minimum limit of 0.81 ng/mL, ranging from 10% to 20%
of the CYP2C19-phenotyped group in both populations. Similarly, with the 30% decrease of mean
abundances, a slight decrease of patient’s response can be observed varying between 10% and 30%
of the CYP2C19-phenotyped group in both populations. Clearly, these observations are not novel,
given that clopi-H4 plasma concentrations are related to the functional status of CYP2C19 within
Asian populations [72]. However, of note was the fact that there was also no significant difference in
the clopi-H4 Cmax between the Malay and Malaysian Chinese population groups in relation to the
CYP2C19-phenotyped group with the ±30% mean abundance values (Figures 11 and 12), further
confirming our earlier findings.
3.5. Step 5: Dose Optimisation in CYP2C19 Poor Metabolisers
In the final step, given the high percentage of subjects with a clopi-H4 Cmax below the minimum
therapeutic concentration under standard dosing procedures (300 mg loading dose followed by 75 mg
for four days), we assessed the impact of a high-dose regimen on clopi-H4 Cmax. Under these revised
dosing conditions, the percentage of subjects with a clopi-H4 Cmax below the minimum therapeutic
concentration decreased to 12% (Malay) and 14% (Malaysian Chinese) (Figure 13). A number of
previous clinical studies have considered the high dose versus standard dose clopidogrel treatment
regimens, particularly for CYP2C19 PM, and identified no significant clinical concerns, with improved
inhibition of platelet aggregation and clinical outcomes [73–76], and our simulations further agreed
with these published findings. Thus, a 600 mg loading dose followed by a 150 mg maintenance dose
may be appropriate for confirmed CYP2C19 PM Malay and Malaysian Chinese patients, particularly
where platelet response is poor.
3.6. Study Limitations and Future Directions for Clopidogrel Use in Malaysia
It is important to address several limitations of the present study. Firstly, although we were able
to develop robust pharmacokinetic models, the limited availability of hepatic CYP2C19 abundance
data and phenotype/genotype specific abundance data in Malay or Malaysian Chinese was a primary
limitation. We utilised existing data from the Chinese population group, which had been previously
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validated by Simcyp, as a surrogate for both Malay and Malaysian Chinese. It could be possible that
inter-ethnic differences exist between Malay and Malaysian Chinese, which may alter the resultant
simulations, although no significant differences in clopi-H4 Cmax were noted in Step 4 (Section 2.4) of
our modelling approach.
The focus of this study has been on LOF alleles (e.g., the PM phenotype). However, other SNPs
have been reported to contribute towards the overall wide inter-individual variability associated with
clopidogrel anti-platelet activity, such as the GOF variant CYP2C19*17 (rs12248560) that defines the
ultra-rapid metaboliser phenotype. Whilst the importance of the LOF alleles are well characterised,
the GOF variants are less well characterised and their impact of antiplatelet activity is contradictory,
as highlighted by a number of meta-analysis studies [77–79]. Further modelling studies should
investigate the relevance of the UM phenotype on clopi-H4 levels to identify whether the GOF alleles
are important for overall clinical efficacy and clopi-H4 plasma concentrations.
Furthermore, there was a lack of published and robust genotyped pharmacokinetic data in
Malaysian subjects, primarily plasma concentration–time profiles, which may have aided in model
validation of the clopidogrel predictions. However, this has been completed by a prior group in
Caucasian subjects [14]. Despite this, further investment in research and development infrastructure
is required to ensure that pharmacokinetic modelling approaches are better integrated into clinical
research to optimise study design and better utilise the clinical data obtained to provide evidence-based
optimised therapy [80].
4. Materials and Methods
Population-based PBPK modelling was conducted using the virtual clinical trials simulator
Simcyp (Simcyp Ltd., a Certara company, Sheffield, UK, Version 16). Simulations were performed
for an exclusive CYP2C19 extensive metaboliser (EM) (CYP2C19*1/*1), poor metaboliser (PM)
(CYP2C19*2/*2), intermediate metaboliser (IM) (CYP2C19*1/*2) and ultrarapid metaboliser (UM)
(CYP2C19*1/*17) population groups. For all simulations, dosing occurred under fasted-conditions
unless otherwise indicated. A detailed list of haplotypes associated with GOF or LOF alleles are
detailed within the PharmGKB database (Accession number: PA124) [19].
4.1. Model Development
A five-stage stepwise approach was implemented for model development, validation and model
refinement (Figure 14), which is fully described below.
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4.1.1. Step 1: Malaysian Population Development
To develop a Malaysian population group for use in pharmacokinetic modelling, the
National Cardiovascular Database (NCVD) Registry [6] was analysed for relevant population-level
anthropometric data relevant to each ethnic group. The NCVD register is a Malaysian nationwide
registry consisting of 33,043 anonymized and voluntary patient records for patients undergoing
acute coronary syndrome and percutaneous coronary intervention, spanning the years 2006–2015.
The NCVD is supported by the Ministry of Health Malaysia and co-sponsored by National Heart
Association of Malaysia, with the aim to gather information about cardiovascular diseases in Malaysia.
Within this database, relevant physiological parameters were limited to only (i) gender; (ii) age; (iii)
weight and (iv) ethnicity.
To develop the Malaysian population group the two largest ethnic groups, Malays and Malaysian
Chinese were considered, as they constitute 50.1% and 22.6% of the total Malaysian population,
respectively [1]. Appropriate anthropometric age–body weight distributions were generated and
used to establish mathematical (polynomial regression) relationships to predict body weight from
age, using TableCurve2D (version, Systat Software, San Jose, CA, USA). The resultant polynomial
regression equations were then applied within the population ‘Demographics’ section of Simcyp
to create user-defined age–weight relationships for each population. Furthermore, blood chemistry
was revised to match report haematocrit and plasma protein concentrations within the Malay and
Malaysian Chinese population groups, as reported in the literature (Table 3).
In the absence of literature reported CYP2C19 hepatic abundance in the Malay and Malaysian
Chinese subjects, the EM, PM, IM and UM phenotypes were allocated a hepatic abundance of 8, 0, 6
and 10 pmol/mg protein, respectively, based upon adaptations detailed within a validated Chinese
population group developed by Simcyp, and which is available from the population library repository
of Simcyp software. These abundances were assumed to be the same for both Malay and Malaysian
Chinese population groups.
Compound Selection and Clinical Studies
A literature search for published clinical studies reporting plasma concentration–time profiles for
ethnicity-specific Malaysian patients (Malay and Chinese) was able to identify repaglinide, tramadol,
rosuvastatin and clopidogrel as therapeutic drugs where pharmacokinetic clinical data was available
for population groups of interest. These studies were used for model development and validation.
The three compounds of interest had previously been developed and validated within Simcyp and are
available within the Simcyp library compound database, with repaglinide developed and pre-validated
by Simcyp [82], tramadol developed and validated by T’jollyn et al. [47] and clopidogrel and its’
primary metabolite (2-oxo-clopidogrel) and secondary metabolite (clopi-H4) previously developed
and validated by Djebli et al. [14].
4.1.2. Step 2: Adult Simulations: Validation with Repaglinide, Tramadol and Rosuvastatin
To confirm the validity of the modelling approaches and the appropriateness of the customised
Malaysian population groups, validation of the population group was conducted using repaglinide,
tramadol and rosuvastatin from six published clinical studies: (i) a single 2 mg oral dose of repaglinide
to healthy adult volunteers [42]; (ii) a single 2 mg oral dose of repaglinide on day 1 and subsequently
2 mg multiple doses orally on day 2 to day 9 in healthy young adults [43]; (iii) a single 2 mg oral
dose of repaglinide dosed to healthy native Han Chinese adult volunteers [44]; (iv) a single 4 mg
oral dose of repaglinide dosed to healthy adult Malay volunteers [45]; (v) a single dose of 100 mg
tramadol given intravenously to adult mixed Malaysian volunteers [46] and (vi) a single oral dose of
40 mg rosuvastatin given Caucasian, Han Chinese and Malays [48] with appropriate hepatic uptake
clearances incorporated as reported by Bae et al. [83]. All simulations replicated the study design
reported by the clinical studies cited above.
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4.1.3. Step 3: Prediction of the Impact of CYP2C19 Polymorphisms on Clopidogrel Pharmacokinetics
in Malaysians
This step simulated the potential impact of SNPs CYP2C19 on the resultant clopi-H4 target plasma
concentration range for patients known to result in a clinical response, namely 0.81 to 13.45 ng/mL [49],
within the Malay and Malaysian Chinese population groups. For all simulation, clopi-H4 concentration
of below 0.81 ng/mL was used as a cut-off value to depict patients who were unresponsive to
clopidogrel treatment. Simulations were stratified across EM, PM, IM and UM phenotypes, and
performed using a validated clopidogrel compound (18) using a trial design of 63 adult subjects who
were administered a 300-mg loading dose (LD) and a 75-mg/day maintenance dose (MD) for four days.
4.1.4. Step 4: Sensitivity Analysis for CYP2C19 Hepatic Abundances
To address the absence of literature reported CYP2C19 hepatic abundances in the Malaysian
population groups, two further scenarios were simulated whereby the mean abundances for the Malay
and Malaysian Chinese population were set at 30% greater/less than that used as default (see Step
1). This allowed for the analysis of the sensitivity of model predictions to changes in abundance to
be simulated through assessing the resulting impact on the number of subjects attaining clopi-H4
target concentrations.
4.1.5. Step 5: Dose Optimisation in CYP2C19 Poor Metabolisers
This step attempted to predict the potential impact of dosage optimisation in the CYP2C19
poor metabolisers’ population, with an aim to recapitulate subjects into the clopi-H4 therapeutic
window range. Simulations were run using the Malay and Malaysian Chinese population groups.
Furthermore, based on the study by Simon et al. [32], the dosing regimen for clopidogrel was increased
to a ‘high-dose’ scenario with a 600 mg loading dose followed by a four-day regimen of 150 mg daily.
4.2. Data Analysis
Clinical plasma concentration–time data points from studies identified in Step 1 (Section 4.1.1)
were extracted using the WebPlotDigitizer v.3.10 (http://arohatgi.info/WebPlotDigitizer/). All
simulations of plasma concentration–time profiles were presented in 5th to 95th percentiles and
either in mean or median unless otherwise specified. For all adult simulations, age ranges and subject
gender ratios were matched, where possible, to reported clinical studies. Where this information was
not cited in clinical studies, a default age range of 40 to 65 years and gender ratio of 50% was selected.
For simulations employing genotypes stratification, unless otherwise stated, a 100-subject simulation
was run in a 10 × 10 trial (10 subjects per trial with 10 trials) per genotype to ensure that reasonable
inter-/intra individual variability is captured within the model simulations.
4.3. Predictive Performance
In all simulations, a prediction to within two-fold of the observed data was generally accepted
as part of the ‘optimal’ predictive performances range despite there being no uniform standard of
acceptance to determine this criterion [84–86]. This acceptance criterion was used in our Cmax and
AUC comparisons with the published clinical data reported. However, this was not used as the sole
determinate for model performance (see Section 4.4).
For the clopidogrel simulations, the target clopi-H4 plasma concentration was set at the
lowest value of 0.81 ng/mL from the range of 0.81–13.45 ng/mL obtained from literature [49]
and used to determine the impact of SNPs CYP2C19 on Malay and Malaysian Chinese
population pharmacokinetics.
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4.4. Visual Predictive Checks
To further validate model predictions where comparison were made to existing clinical studies, a
visual predictive checking (VPC) strategy was adopted. This approach was described at the 2012 FDA
Pediatric Advisory Committee (US Food and Drug Administration, 2012) [87]. In this approach, to
graphically validate the predictability of the model, the 5th and 95th percentiles (along with mean or
median) of predicted concentration–time profiles (generated from Simcyp) were graphically displayed
along with the observed data for any validation data sets to ensure predicted data points largely
overlapped with those from the observed data sets, which should contain (where possible) some
measure of spread of observed plasma concentration data (e.g., a standard deviation for each mean
concentration point).
5. Conclusions
Cardiovascular disease (CVD) is a leading cause of mortality and is increasingly prevalent in
Malaysia, which places the Malaysian healthcare system at ever increasing risks and cost-burdens
for treatment of patients. Given the unique ethnic diversity of the Malaysian population group,
evidence-based approaches should account for the individual characteristics of patients rather than
focusing on an average patient from a carefully selected patient population. Pharmacokinetic modelling
can provide this approach through carefully developed and validated population models which can
be applied to study a drug’s pharmacokinetics in different geographical regions. This approach was
applied to clopidogrel and illustrated the impact of a PM phenotype on reducing clopi-H4 Cmax,
which could be partially recovered using a high-dose strategy (600 mg loading dose followed by
150 mg maintenance dose), which resulted in an approximate 50% increase in subjects attaining the
minimum clopi-H4 plasma concentration for a therapeutic effect. Furthermore, we illustrated limited
variation clopi-H4 pharmacokinetics between the two key ethnic groups, Malays and Malaysian
Chinese, suggesting that inter-ethnic differences within Malaysia may not impact upon clopidogrel
therapy. It should be noted, however, that the current lack of existing clopidogrel pharmacokinetics
data in multi-ethnic population groups is lacking within Malaysian populations, and this data would
be valuable to support the work presented within this manuscript and to also aid in validating the
outcomes presented.
This study has illustrated the benefit of the application of pharmacokinetic modelling, which
incorporates pharmacogenetics information, to mixed ethnic population groups. The current lack of an
integrated approach within Malaysia, in addition to the sparse routine application of pharmacokinetic
modelling to clinical data, should be addressed to support better clinical drug decision-making.
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